Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...
A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people ...
Protein crystallization at the SER-CAT beamline at Argonne’s Advanced Photon Source proved key to the discovery of a new HIV vaccine candidate.
An American biochemist whose research has helped scientists make inroads on treating coronavirus and HIV has won this year’s ...
This research on a T-cell–targeting vaccines in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of ...
An effective HIV-1 vaccine must therefore elicit antibodies that can neutralize many variants of the virus. While broadly neutralizing antibodies (bnAbs) have been isolated from HIV-1 infected ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback